Increased levels of erythropoietin in nipple aspirate fluid and in ductal cells from breast cancer patients

Cellular Oncology

Volumn 30, Issue 1, 2008, Pages 51-61

  Mannello, Ferdinando ^a   Fabbri, Laura ^a   Ciandrini, Eleonora ^a   Tonti, Gaetana A ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

Benign breast disease; Breast cancer; Erythropoietin; Immunocytochemistry; Milk; Nipple aspirate fluid; Serum

Indexed keywords

ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CELL; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; NIPPLE ASPIRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; ERYTHROPOIETIN; FEMALE; HUMANS; IMMUNOPRECIPITATION; MICROSCOPY, IMMUNOELECTRON; MIDDLE AGED; MILK, HUMAN; NIPPLES;

EID: 38549117707     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. G. Acs, P. Acs, A.M. Beckwith et al., Erythropoietin and erythropoietin receptor expression in human cancer, Cancer Res. 61 (2001), 3561-3565.
2. G. Acs, M. Chen, X. Xu et al., Autocrine erythropoietin signalling inhibits hypoxia-induced apoptosis in human breast carcinoma cells, Cancer Lett. 214 (2004), 243-251.
3. G. Acs, P.J. Zhang, T.R. Rebbeck et al. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma, Cancer 95 (2002), 969-981.
4. M.O. Arcasoy, K. Amin, A.F. Karayal et al., Functional significance of erythropoietin receptor expression in breast cancer, Lab. Invest. 82 (2002), 911-918.
5. M.O. Arcasoy, X. Jiang and Z.A. Haroon, Expression of erythropoietin receptor splice variants in human cancer, Biochem. Biophys. Res. Commun. 307 (2003), 999-1007.
6. D.L. Beckman, L.L. Lin, M.E. Quinones et al., Activation of the erythropoietin receptor is not required for internalisation of bound erythropoietin, Blood 94 (1999), 2667-2675.
7. J. Bohlius, O. Weingart, S. Trelle et al., Cancer-related anaemia and recombinant human erythropoietin - an updated overview, Nat. Clin. Pract. Oncol. 3 (2006), 152-164.
8. R.F. Bohnen, M. Banisadre, R.N. Gulbrandson et al., Erithrocytosis caused by and erythropoietin-producing breast adenocarcinoma, West. J. Med. 152 (1990), 417-418.
9. G.C. Buehring, A. Letscher, K.M. McGirr et al., Presence of epithelial cells in nipple aspirate fluid is associated with subsequent breast cancer: a 25-year prospective study, Breast Cancer Res. Treat. 98 (2006), 63-70.
10. A. Burton, Is it all over for erythropoietin? Lancet Oncol. 8 (2007), 285.
11. R.S. Dua, C.M. Isacke and G.P. Gui, The intraductal approach to breast cancer biomarker discovery, J. Clin. Oncol. 24 (2006), 1209-1216.
12. E.A. Dunlop, M.J. Percy, M.P. Boland et al., Induction of signalling in nonerythroid cells by pharmacological levels of erythropoietin, Neurodegener. Dis. 3 (2006), 94-100.
13. S. Erbayraktar, O. Yilmaz, N. Gokmen et al., Erythropoietin is a multifunctional tissue-protective cytokine, Curr. Hematol. Rep. 2 (2003), 465-470.
14. C.J. Fabian, B.F. Kimler, M.S. Mayo et al., Breast-tissue sampling for risk assessment and prevention, Endocr. Rel. Cancer 12 (2005), 185-213.
15. F. Farrell and A. Lee, The erythropoietin receptor and its expression in tumor cells and adult tissues, Oncologist 9(Suppl. 15) (2004), 18-30.
16. J.W. Fisher, Erythropoietin: physiology and pharmacology update, Exp. Biol. Med. 228 (2003), 1-14.
17. M. Gassmann, K. Heinicke, J. Soliz et al., Non-erythroid functions of erythropoietin, Adv. Exp. Med. Biol. 543 (2003), 323-330.
18. D.A. Gewirtz, X. Di, T.D. Walker et al., Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs, Clin. Cancer Res. 12 (2006), 2232-2238.
19. M.E. Hardee, M.O. Arcasoy, K.L. Blackwell et al., Erythropoietin biology in cancer, Clin. Cancer Res. 12 (2006), 332-339.
20. M.E. Hardee, Z.N. Rabbani, M.O. Arcasoy et al., Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity, Mol. Cancer Ther. 5 (2006), 356-361.
21. A. Jemal, R. Siegel, E. Ward et al., Cancer statistics 2007, CA-Cancer J. Clin. 57 (2007), 43-66.
22. S.E. Juul, Y. Zhao, J.B. Dame et al., Origin and fate of erythropoietin in human milk, Pediatr. Res. 48 (2000), 660-667.
23. B.L. King and S.M. Love, The intraductal approach to the breast: raison d'être, Breast Cancer Res. 8 (2006), 206.
24. P.J. Kling, T.M. Sullivan, R.A. Roberts et al., Human milk as a potential enteral source of erythropoietin, Pediatr. Res. 43 (1998), 216-221.
25. P.J. Kling, Roles of erythropoietin in human milk, Acta Pediatr. Suppl. 91 (2002), 31-35.
26. S.M. Kumar, G. Acs, D. Fang et al., Functional erythropoietin autocrine loop in melanoma, Am. J. Pathol. 166 (2005), 823-830.
27. C. Kunz, M. Rodriguez-Palmero, B. Koletzko et al., Nutritional and biochemical properties of human milk. Part I: General aspects, proteins, and carbohydrates, Clin. Perinatol. 26 (1999), 307-333.
28. M.P. Fay and E.J. Feuer, Confidence intervals for directly standardised rates: a method based on the gamma distribution, Stat. Med. 16 (1998), 791-801.
29. P.H. Lai, R. Everett, F.F. Wang et al., Structural characterization of human erythropoietin, J. Biol. Chem. 261 (1986), 3116-3121.
30. S. Lai and J.R. Grandis, Understanding the presence and function of erythropoietin receptor on cancer cells, J. Clin. Oncol. 24 (2006), 4675-4676.
31. K.R. LaMontagne, J. Butler, D.J. Marshall et al., Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models, Mol. Cancer Ther. 5 (2006), 347-355.
32. T.R. Lappin, A.P. Maxwell, P.G. Johnston, EPO's alter ego: erythropoietin has multiple actions, Stem Cells 20 (2002), 485-492.
33. T.R. Lappin, A.P. Maxwell and P.G. Johnston, Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia, Oncologist 12 (2007), 362-365.
34. R.D. Lester, M. Jo, W.M. Campana et al., Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/MAPK-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia, J. Biol. Chem. 280 (2005), 39273-39277.
35. B. Leyland-Jones, Breast cancer trial with erythropoietin terminated unexpectedly, Lancet Oncol. 4 (2003), 459-460.
36. J. Li, J. Zhao, X. Yu et al., Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid, Clin. Cancer Res. 11 (2006), 8312-8320.
37. M. Malatesta, F. Mannello, G. Bianchi et al., Biochemical and ultrastructural features of human milk and nipple aspirate fluids, J. Clin. Lab. Anal. 14 (2000), 330-335.
38. M. Malatesta, F. Mannello, M. Sebastiani et al., Prostate-specific antigen found in Type I breast cyst fluids is a secretory product of the apocrine cells lining breast gross cysts, Breast Cancer Res. Treat. 57 (1999), 157-163.
39. F. Mannello and M. Sebastiani, Zymographic analyses and measurement of matrix metalloproteinase-2 and -9 in nipple aspirate fluids, Clin. Chem. 49 (2003), 1546-1550.
40. F. Mannello, G.A. Tonti, S. Pagliarani et al., The 8-epimer of prostaglandin F2a, a marker of lipid peroxidation and oxidative stress, is decreased in the nipple aspirate fluid of women with breast cancer, Int. J. Cancer 120 (2007), 1971-1976.
41. F. Mannello, Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle, J. Clin. Oncol. (2007), in press.
42. M. Milano and M. Schneider, Epo in cancer anemia: benefits and potential risks, Crit. Rev. Oncol./Hematol. 62 (2007), 119-125. DOI 10.1016/j.critrevonc.2006.11.011.
43. N.L. Petrakis, Studies on the epidemiology and natural history of benign breast disease and breast cancer using nipple aspirate fluid, Cancer Epidemiol. Biomarker Prev. 2 (1993), 3-10.
44. D. Ribatti, A. Marzullo, B. Nico et al., Erythropoietin as an angiogenic factor in gastric carcinoma, Histopathology 42 (2003), 246-250.
45. E.R. Sauter, E. Ross, M. Daly et al., Nipple aspirate fluid: a promising non invasive method to identify cellular markers of breast cancer risk, Br. J. Cancer 76 (1997), 494-501.
46. S.E. Singletary, J.L. Connolly et al., Breast cancer staging: working with the sixth edition of the AJCC cancer staging manual, CA-Cancer J. Clin. 56 (2006), 37-47.
47. D.P. Steensma, C.L. Loprinzi, Erythropoietin use in cancer patients: a matter of life and death?, J. Clin. Oncol. 23 (2005), 5865-5868.
48. F. Verdier, P. Walrafen, N. Hubert et al., Proteasome regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors, J. Biol. Chem. 275 (2000), 18375-18381.
49. P. Walrafen, F. Verdier, Z. Kadri et al., Both proteasome and lysosomes degrade the activated erythropoietin receptor, Blood 105 (2005), 600-608.
50. D.N. Waterhouse, K.A. Gelmon, R. Klasa et al., Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers, Curr. Cancer Drug Targets 6 (2006), 455-489.
51. A.W. Wognum, P.M. Lansdorp, C.J. Eaves et al., Use of a sensitive bioimmunosorbent assay to isolate and characterize monoclonal antibodies to biologically active human erythropoietin, Blood 71 (1998), 1731-1738.
52. Y. Yasuda, Y. Fujita, S. Matsuda et al., Erythropoietin is involved in growth and angiogenesis in malignant tumour of female reproductive organs, Carcinogenesis 23 (2002), 1797-1805.